Health · Medical Research · 4 hrs ago

Two Experimental Approaches Show Promise Against Advanced Prostate Cancer

Two Experimental Approaches Show Promise Against Advanced Prostate Cancer

Researchers are testing two different experimental approaches to advanced prostate cancer, which can stop responding to treatments that reduce or block testosterone.

One approach, the daily drug bavdegalutamide, was tested in a clinical trial involving patients with advanced disease at three institutions.

About 60 percent of patients with T878/H875 mutations had a large drop in a blood marker linked to prostate cancer, compared with 3 to 4 percent of patients with other gene profiles.

The mutation group also went a median of 11 months before their cancer worsened on scans or they died, compared with about 4 to 5 months for the others.

The trial was small and had no control group, and the results do not show that the drug shrinks tumors or helps patients live longer; side effects included nausea, fatigue, vomiting and diarrhea.

A separate University of Michigan team developed DALTAC-1, which links two proteins involved in cancer growth, and tested it in cells, human-cell organoids and mice.

DALTAC-1 has not been tested in people; researchers are working to identify a candidate for human trials, while its maker is prioritizing a related drug with fewer side effects whose trial is expected to finish in May 2027.

2 sources

Related

What people are saying

Arul M. Chinnaiyansenior study author and director of the Michigan Center for Translational Pathology
Our molecule acts like a molecular brace, connecting these two cancer-driving proteins in an abnormal configuration that traps them in an inactive state
via SciTechDaily
Daniel Petrylakoncologist at Yale University
The drug degrades the receptors for testosterone, which control prostate cancer growth
via ScienceAlert
These are the parameters that indicate a positive response.
via ScienceAlert
Shaomeng Wangsenior study author and director of the Michigan Center for Therapeutic Innovation
Our optimized molecule is approximately 1,000 times more potent in tumor cells than the combination of inhibitors targeting these proteins separately, while sparing normal cells that lack these interactions.
via SciTechDaily